Here are the top 5 biosimilar articles for the week of April 21, 2025. Number 5: Trastuzumab biosimilars saw significant ...

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the ...

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy ...

To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like ...

A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the ...

Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...